Incyte Stock Today
| INCY Stock | USD 102.97 1.81 1.79% |
PerformanceWeakest
| Odds Of DistressTiny
|
Incyte is trading at 102.97 as of the 18th of February 2026; that is 1.79% increase since the beginning of the trading day. The stock's open price was 101.16. Incyte has a very small chance of experiencing financial distress in the next few years, but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 20th of November 2025 and ending today, the 18th of February 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 4th of November 1993 | Category Healthcare | Classification Health Care |
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware. The company has 199.01 M outstanding shares of which 11.19 M shares are currently shorted by private and institutional investors with about 5.58 trading days to cover. More on Incyte
Moving against Incyte Stock
Incyte Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| President CEO | William Meury | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP 500 Index, NASDAQ Biotechnology, ARCA Biotechnology, Dow Jones Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Excise Tax Activities | Animal Testing | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsIncyte utilizes debt financing to potentially enhance returns on invested capital. The relationship between total debt and total assets provides valuable insight into Incyte's leverage profile, showing how much of Incyte's resources are funded through borrowing.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Incyte (INCY) is traded on NASDAQ Exchange in USA and employs 2,844 people. Incyte is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Large-Cap' category with a current market capitalization of 20.12 B. Incyte conducts business under Biotechnology sector and is part of Health Care industry. The entity has 199.01 M outstanding shares of which 11.19 M shares are currently shorted by private and institutional investors with about 5.58 trading days to cover.
Incyte currently holds about 2.72 B in cash with 1.41 B of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 12.24.
Check Incyte Probability Of Bankruptcy
Ownership AllocationThe majority of Incyte outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Incyte to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Incyte. Please pay attention to any change in the institutional holdings of Incyte as this could imply that something significant has changed or is about to change at the company.
Check Incyte Ownership Details
Incyte Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Morgan Stanley - Brokerage Accounts | 2025-06-30 | 2.6 M | |
| Robeco Institutional Asset Management Bv | 2025-06-30 | 2.4 M | |
| Ubs Asset Mgmt Americas Inc | 2025-06-30 | 2 M | |
| Charles Schwab Investment Management Inc | 2025-06-30 | 1.7 M | |
| Northern Trust Corp | 2025-06-30 | 1.7 M | |
| Man Group Plc | 2025-06-30 | 1.6 M | |
| Bellevue Group Ag | 2025-06-30 | 1.6 M | |
| Legal & General Group Plc | 2025-06-30 | 1.6 M | |
| Norges Bank | 2025-06-30 | 1.4 M | |
| Baker Bros Advisors Lp | 2025-06-30 | 30.7 M | |
| Vanguard Group Inc | 2025-06-30 | 20.1 M |
Incyte Historical Income Statement
Incyte Stock Against Markets
Incyte Corporate Management
| Sheila JD | General VP | Profile | |
| Thomas Tray | Chief Finance | Profile | |
| Pamela Murphy | Vice Communications | Profile | |
| Patrick Mayes | Vice Research | Profile | |
| Christine Chiou | Head Relations | Profile | |
| PharmD MBA | Executive America | Profile |
Additional Tools for Incyte Stock Analysis
When running Incyte's price analysis, check to measure Incyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Incyte is operating at the current time. Most of Incyte's value examination focuses on studying past and present price action to predict the probability of Incyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Incyte's price. Additionally, you may evaluate how the addition of Incyte to your portfolios can decrease your overall portfolio volatility.